NCT03136146
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Recurrent Burkitt Lymphoma
Explore clinical trials studying Recurrent Burkitt Lymphoma. Study availability and eligibility vary by location and protocol.
11 public trials
2 recruiting studies
Recurrent Burkitt Lymphoma trial results
NCT01371630
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, +23 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Not yet recruiting
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
NCT07724457
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +18 more
- Locations
-
Not specified
Active, not recruiting
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
NCT02797470
- Conditions
- Blood-Borne Infections, Burkitt Lymphoma, Communicable Diseases, +41 more
- Locations
-
- UC San Diego Moores Cancer Center La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- UCSF Medical Center-Parnassus San Francisco, California, United States
- Memorial Sloan Kettering Cancer Center New York, United States
Active, not recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
Active, not recruiting
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03015896
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT02992522
- Conditions
- B-Cell, B-Cell Lymphoma, Unspecified, Burkitt Lymphoma, +30 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT02568553
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
- Conditions
- AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, Burkitt Lymphoma, +26 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States